Most respondents 74% ; prescribed a selective serotonin reuptake inhibitor SSRI ; as initial antidepressant therapy. Sertraline 35% ; and paroxetine 21% ; were the most common. Tricyclic antidepressants TCAs ; were chosen for 11% of respondents and nefazodone, moclobemide and venlafaxine, combined, accounted for 14%. Over 88% of respondents indicated their choice of antidepressant was influenced by efficacy and adverse effect profiles. Reasons specified included proven effectiveness, past prescribing success and lower incidence of adverse effects with the SSRIs and newer antidepressants. Most prescribers 84% ; of SSRIs would discuss the frequent adverse effects with the patient and of these 13% would also provide management advice for adverse effects, especially if symptoms persisted after 1-2 weeks. All the prescribers of nefazodone, venlafaxine and moclobemide would provide the patient with specific adverse effects. Half of these prescribers would also discuss management of adverse effects. The prescribers of TCAs would discuss the common adverse effects and included the warning to avoid alcohol and or caution about driving machinery. Other important information given to the patient included delay in onset of action, timeframe of treatment, and importance of compliance. The majority of respondents would not prescribe any other drug therapy 64% ; . Of the 36% who would prescribe other drug therapy, 32% would prescribe a concomitant benzodiazepine. Only 4% indicated they would change antidepressant therapy if initial choice gave a poor response!

Shum H.Y.I., Zheng L., Taylor G., Tipoe G.L., Lam W.K., Ho J.C.M. and Tsang K.W.T., Down regulation of INOS by Pseudomonas aeruginosa pyocyanin in human bronchial organ cultures Abstract ; , European Respiratory Journal. 1999, 13 suppl: P1578. Publication No. : 50001 ; Shum H.Y.I., Zheng L., Taylor G., Tipoe G.L., Lam W.K. and Tsang K.W.T., Down regulation of iNOS by Pseudomonas aeruginosa pyocyanin in human bronchial organ cultures Abstract ; , American Journal of Respiratory and Critical Care Medicine. 2000, 161 3 ; : A180. Publication No. : 50063 ; Shum H.Y.I., Zheng L., Fung P.C.W., Taylor G., Tipoe G.L., Lam W.K. and Tsang K.W.T., Pseudomonas aeruginosa pyocyanin down-regulates iNOS in human bronchial mucosa Abstract ; , Hong Kong Practitioner. 2000, 22 suppl 2: 57. Publication No. : 50355 ; Shum I.H.Y., Shum I.H.Y., Zheng L., Taylor G., Tipoe G.L., Lam W.K., Ho J.C.M. and Tsang K.W.T., Down regulation of inducible nitric oxide synthase iNOS ; by pseudomonas aeruginosa PA ; pyocyanin PYO ; in human bronchial organ cultures, American Journal of Respiratory and Critical Care Medicine. 2000, 161: A180. Publication No. : 49638 ; Shum I.H.Y., Zheng L., Taylor G., Tipoe G.L., Lam W.K., Fung P.C.W., Ho J.C.M. and Tsang K.W.T., Pseudomonas aeruginosa pyocyanin PYO ; down-regulates inducible nitric oxide synthase iNOS ; expression in human bronchus, The Hong Kong Practitioner. 2000, 22 No. 2 Supplement: 57 No. S-RC-6. Publication No. : 54863 ; Sin S.Y., Tang M.H.Y., Chan V.N.Y., Leung S.Y. and Chan K.L., Follow up of a year old child after in utero muscle biopsy for suspected Duchenne Muscular Dystrophy DMD ; by DNA linkage analysis Poster presentation ; , 2nd Hong Kong Medical Genetics Conference, Hong Kong, October 15-17, 1999 Publication No. : 47965 ; Talley .N.J., Axon A., Bytzer P., Holtmann G., Lam S.K. and Van-Zanten S., Management of uninvestigated and functional dyspepsia: a working party report for the World Congresses of Gastroenterology, Alimentary Pharmacology & Therapeutics. 1999, 13: 1135-48. Publication No. : 51688 ; Tan K.C.B., Shiu S.W.M. and Janus E.D., Cholesteryl ester transfer protein activity and hyperalphalipoproteinaemia in Chinese, The XIIth International Symposium on Atherosclerosis. Stockholm, Sweden. 2000. Publication No. : 51203 ; Tan K.C.B., Shiu S.W.M. and Janus E.D., Cholesteryl ester transfer protein gene mutations in the Chinese population of Hong Kong., The 2nd Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases, Chiang Mai, Thailand. 2000. Publication No. : 51200 ; Tan K.C.B., Shiu S.W.M. and Chu B.Y.M., Effect of the -514 polymorphism in the hepatic lipase gene on postheparin plasma hepatic lipase in Chinese subjects., The XIIth International Symposium on Atherosclerosis, Stockholm, Sweden. 2000. Publication No. : 51202 ; Tan K.C.B. and Shiu S.W.M., Hepatic lipase and LDL subfraction distribution in patients with type 2 diabetes mellitus., The 4th International Diabetes Federation Western Pacific Region Congress, Sydney, Australia. 1999. Publication No. : 51194 ; Tan K.C.B., Ai V.H.G., Chow W.S., Chau M.T., Leong L. and Lam K.S.L., LDL subfraction pattern and vasomotor function in type 2 diabetes mellitus., Huaxia Congress of Endocrinology, Beijing, China. 1999. Publication No. : 51198 ; Tang S., Sacks S.H., Lan H.Y., Chan D.T.M. and Lai K.N., Transferrin overload mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells [Abstract presented at the 32nd Annual Meeting of the American Society of Nephrology, November 1-8, Miami Beach, Florida, USA], Journal of and oretic.

Certain medications, notably anti-depressants, steroid medications, certain high blood pressure drugs, and seizure medications can also cause increased body weight. Updated June 2006 Costs for April 2006 ; Generic Name and Dose Paroxetine 20mg tablet Paroxetine 20mg tablet Paroxetine 30mg tablet Paroxetine 30mg tablet Paroxetine 30mg tablet Paroxetine 40mg tablet Paroxetine 40mg tablet Paroxetine 40mg tablet Paroxetine 12.5mg sustained release tablet Paroxetine 25mg sustained release tablet Paroxetine 37.5mg sustained release tablet Sertraline 25mg tablet Sertraline 50mg tablet Sertraline 100mg tablet Venlafaxime 37.5mg sustained release capsule Venlafaxije 25mg tablet Venlafaxine 37.5mg tablet Venlafaxine 75mg sustained release capsule Venlafaxine 50mg tablet Venlafaxine 75mg tablet Venlafaxine 150mg sustained release capsule Venlafaxine 100mg tablet Brand Name1 Pexeva Generic Paxil Pexeva Generic Paxil Pexeva Generic Paxil CR Paxil CR Paxil CR Zoloft Zoloft Zoloft Effexor XR Effexor Effexor Effexor XR Effexor Effexor Effexor XR Effexor Drug is a Generic No Yes No No Yes No No Yes No No No Frequency of Use per Day2 One One One One One One One One One One One One One One One Two Two One Two Two One Two Average Monthly Cost3 $100 $59 $120 $104 $66 $127 $109 $67 $109 $113 $118 $104 $101 $113 $145 $155 $125 $152 $165 $133 $163 and microzide. The Harvard Medication Algorithm Project HMAP ; : The Harvard School of Medicine developed a Psychopharmacology Algorithm program at the Harvard South Shore Department of Psychiatry. This project began in 1997 with the goals of formulating evidence-based treatment guidelines for the treatment of mental disorders and making these guidelines available to clinicians on-line. HMAP algorithms were created on the basis of high quality empirical studies, field trials, expert opinion, peer review and review of other guidelines. HMAP offers a free web site where any physician or psychiatrist can consult the Harvard algorithms regarding specific patients and clinical situations, because hcl.
A double-blind, randomised, 12-week comparison study of the safety and efficacy of venlafaxlne and fluoxetine in moderate to severe depression in general practice. Primary Care Psychiatry, 3, 51 58. Psychiatry and eulexin. Venlafaxine treatment supports evidence that a significant increase in total cholesterol is associated with the remission of depressive symptoms.55 Conversely, numerous studies have established a significant correlation between low serum cholesterol and suicidal ideation.5658 Study Limitations This study was carried out in 15 centers in the United States, which contributed the majority of the patients 182 ; , and 16 centers in Europe, which contributed 53 patients. In multicenter studies, there may be a concern that disproportionate contribution of patients from some centers may influence the overall results. In this study, the number of patients per site ranged from 6 to 16 the United States, with a mean of 12.13 and median of 11.5. For the European sites, the number of patients per site ranged from 0 to 14, with a mean of 3.31 and median of 2.5. To address the possibility of study center influence, center was used as a factor in the ANCOVA with pooling of the sites that enrolled only a few patients. In long-term studies, there is the possibility that psychotherapy may be delivered, which might have an effect on the results. Psychotherapy that had already been established was not proscribed in our study, but any change during the study was not permitted. The importance of this aspect of the protocol was emphasized at the prestudy investigator meeting, and it was emphasized that the interaction with the patients should be kept as business-like as possible to avoid delivering "psychotherapy." It is therefore unlikely, but nevertheless possible, that some investigators delivered some form of psychotherapy. However, if that were the case and psychotherapy were effective in reducing the risk of recurrence, one could expect that it might be more difficult to differentiate between treatment groups. The 2-week taper period for patients who were discontinued onto placebo treatment might be considered relatively short. However, the period chosen conforms to the dosing instructions in the venlafax9ne IR package insert59 and is consistent with those in other studies of venlafaaxine that included a flexible taper period at the end of the study of up to weeks. The rate of sexual side effects was lower in this study than is often reported with SSRIs, and this may have been influenced by the method of collecting side effects, which was self-report. In studies for the registration of drugs, great emphasis is placed on collecting spontaneously reported adverse event information, and the study centers are instructed to avoid asking any leading questions. CONCLUSION The results of the present study provide robust evidence that maintenance treatment with venlafaxine is effective in reducing the risk of a new episode of depression.

The company claimed the agency had looked over safety issues surrounding a generic version of the drug. 2 Study Design and Findings This double-blind, randomized, placebo-controlled, multi-center, six-week study enrolled adults diagnosed with major depressive disorder who had an inadequate response to one or more ADTs. After a seven to 28-day screening phase, adults in this study underwent an eight-week prospective treatment phase with one ADT plus single-blind placebo to confirm their inadequate response to ADT. The ADTs included escitalopram, fluoxetine, paroxetine controlled release, sertraline or venlafaxine extended release, dosed per label guidelines. A total of 362 adults with inadequate response then entered the six-week randomized treatment phase during which they continued their ADT plus double-blind adjunctive placebo or adjunctive aripiprazole 2-20 mg day ; . The primary efficacy endpoint was the mean change from baseline the end of the prospective treatment phase to the end of the randomized treatment phase in a standard measure called the MADRS Total Score, which can range from 0 no symptoms ; to 60 points most severe symptoms ; . A reduction in MADRS Total Score represents improvement in depressive symptoms. Some of the secondary endpoints included Sheehan Disability Scale SDS ; , MADRS-measured remission and response rates and Clinical Global Impression-Severity of Illness CGI-S ; score. For the primary endpoint, the study showed that adults taking adjunctive aripiprazole had a greater reduction in MADRS Total Score from baseline compared to placebo -8.8 vs. -5.8 points, p-value less than 0.001 ; . The discontinuation rate due to an adverse event for adults taking add-on aripiprazole was 3.3 percent and 2.3 percent for placebo. The most common adverse events in the add-on aripiprazole and add-on placebo groups, respectively, greater than or equal to 5 percent and at least twice the incidence of placebo ; were akathisia 23.1 percent vs. 4.5 percent ; , insomnia 7.7 percent vs. 2.3 percent ; , restlessness 14.3 percent vs. 3.4 percent ; , upper respiratory tract infection 8.2 percent vs. 4 percent ; , and blurred vision 6.6 percent vs. 1.7 percent and efavirenz and venlafaxine.